According to the United Nations Office on Drugs and Crime, nearly five percent of the global adult population consumed some sort of prohibited drug at least once in 2015. That percentage escalates steeply if we consider it within the U.S., a country that has been marred by the cases of substance abuse for several decades. Similar incrementing numbers are being observed in European nations too and as a result, resilient measures are now being undertaken by respective governments to overcome this cause of premature death among the adults. Consequently, the global drugs of abuse testing market is flourishing, with the demand projected to expand at a notable CAGR of 5.4% during the forecast period of 2017 to 2025. The analysts of the report have evaluated that there were opportunities worth US$4,443.9 mn in the global drugs of abuse testing market in 2017. By the end of the aforementioned forecast period, 2025, the valuation of the market is estimated to swell up to US$6,781.6 mn.
The market for drugs of abuse testing, which can be an in-house or onsite examination of drugs within a human body, is gaining traction from a number of factors such as advancements in technology of analyzers, increasing availability of forbidden drugs, and growing emphasis on work place screening among the urban populations. The advent of testing devices that are overcoming the need for a sample of saliva, urine, or blood to be taken to a laboratory is foreseen as a major boon for the drugs of abuse testing market. On the other hand, lack of awareness regarding the availability of advanced drug testing devices and its consideration as a violation of privacy rights in some countries are a few restraints hampering the growth of the market.
Consumables Provide for the Major Chunk of Overall Demand
On the basis of product type, the drugs of abuse testing market has been segmented into three major sub segments of analyzers, rapid testing devices, and consumables. Between these segments, consumables accounted for around 35.7% market share (in terms of revenue), in 2016. One of the most common and beneficial uses of consumables is that it is used in every application for taking the sample. The segment of consumables includes fluid collection devices and rest all other reagents used in carrying out the laboratory test. The rapid testing devices are most convenient devices for carrying out the preliminary test for detection of drug in the human body owing to its portability. The test conducted using rapid testing devices usually denoted positive or negative results. If further detailed investigation is required then the testing are done in the laboratories using the analyzers.
Request a Sample of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1746
Based on the sample type, the drugs of abuse testing market has been classified into saliva, blood, sweat, hair, and urine and breath. The urine sample type segment accounted for the major share of 39.1% of the global drugs of abuse testing market in 2016, followed by saliva. Based on testing type the market for drugs of abuse is bifurcated into pain management testing, criminal justice testing, and work place screening. The criminal justice testing segment accounted for 39.6% share of the total demand in 2016. Based on the end user, the drugs of abuse testing market has been further categorized into hospitals, diagnostic laboratories, on the spot testing, and forensic laboratories.
The U.S. to Sustain North America as the Most Lucrative Region
Geographically, the global drugs of abuse testing market has been categorized into five regions: North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America accounted for a 49.3% of the total demand in 2016, followed by Europe. Demand for rapid testing devices in North America is high as the government is regularizing the rules and regulation for illicit drugs consumption. By the end of 2025, the North America drugs of abuse testing market is estimated to be worth US$3,467.2 mn, expanding at an above-average CAGR of 5.8% during the forecast period of 2017 to 2025.
Request a Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1746
Thermo Fisher Scientific Inc., Siemens Healthineers, F. Hoffmann-La Roche Ltd., Drägerwerk AG & Co. KGaA, Laboratory Corporation of America Holdings, Danaher Corporation (Beckman Coulter, Inc.), and Abbott Laboratories are some of the key players that have been profiled in this report.